NewswireToday - /newswire/ -
Philadelphia, PA, United States, 2009/06/19 - ERT (NASDAQ: ERES), a leading provider of centralized ECG and eClinical technology, ePRO and other services to the biopharmaceutical, medical device and related industries, closed the stock market on 18 June by ringing the famous NASDAQ bell.
Joel Morganroth, Chairman of the Board and Chief Scientific Officer and Michael McKelvey, CEO at ERT rang the NASDAQ MarketSite closing bell in New York's Times Square.
Michael McKelvey took the opportunity to publicly thank all ERT employees, customers and shareholders for their continuing support. Guests at the event included Board members and the senior management team - who joined Joel Morganroth and Michael McKelvey on stage for the ringing of the official closing bell.
Michael McKelvey said, "We are extremely honored, proud and excited to have been invited by the NASDAQ Stock Exchange to participate in the closing bell ceremony. Ringing the closing bell has given us a unique opportunity to publicly thank our employees, customers and shareholders for helping us get ERT to where it is today. It was also an excellent opportunity to further reinforce our presence within the NASDAQ community."
The highly celebrated event was beamed across the city streets courtesy of the landmark MarketSite Tower, while millions of viewers worldwide watched on the NASDAQ Webcam and participating television networks. The company's ticker symbol was displayed on the MarketSite Tower.
ERT is a leading provider of technology and services to the biopharmaceutical and medical device industries around the world. ERT products and services are all enabled by the Company's innovative technology platform - EXPERT. EXPERT is a robust, secure and validated clinical-research workflow-processing system that powers centralized electronic data collection, data management and information exchange.
ERT will also be showcasing its portfolio of products and services on booth # 507 at the 45th Annual DIA Meeting, 21-25 June 2009 in San Diego, California, USA.
Based in Philadelphia, PA, ERT (eResearchTechnology, Inc.) is a provider of technology and services to the global biopharmaceutical and medical device industries. The Company is the market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The Company also provides technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis and distribution of clinical data in all phases of clinical development.
Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, including, but not limited to, 2009 financial guidance, involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.